Logo image of CTK

COOTEK CAYMAN INC-ADR (CTK) Stock Fundamental Analysis

NYSE:CTK - New York Stock Exchange, Inc. - US21718L1026 - ADR

0.9111  +0.02 (+2.36%)

Fundamental Rating

3

Overall CTK gets a fundamental rating of 3 out of 10. We evaluated CTK against 284 industry peers in the Software industry. CTK has a bad profitability rating. Also its financial health evaluation is rather negative. CTK has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CTK was profitable.
CTK Yearly Net Income VS EBIT VS OCF VS FCFCTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M -40M

1.2 Ratios

Industry RankSector Rank
ROA -46.09%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTK Yearly ROA, ROE, ROICCTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 500 1K 1.5K

1.3 Margins

Industry RankSector Rank
OM -4.36%
PM (TTM) -5.95%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTK Yearly Profit, Operating, Gross MarginsCTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, CTK has about the same amount of shares outstanding.
The debt/assets ratio for CTK is higher compared to a year ago.
CTK Yearly Shares OutstandingCTK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 200M 400M 600M
CTK Yearly Total Debt VS Total AssetsCTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 1.63, we must say that CTK is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for CTK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.63
ROIC/WACCN/A
WACCN/A
CTK Yearly LT Debt VS Equity VS FCFCTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.82 indicates that CTK may have some problems paying its short term obligations.
CTK has a Quick Ratio of 0.82. This is a bad value and indicates that CTK is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.82
CTK Yearly Current Assets VS Current LiabilitesCTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 130.88% over the past year.
Looking at the last year, CTK shows a decrease in Revenue. The Revenue has decreased by -1.04% in the last year.
CTK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 89.97% yearly.
EPS 1Y (TTM)130.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y26.61%
Revenue growth 5Y89.97%
Sales Q2Q%-48.23%

3.2 Future

The Earnings Per Share is expected to grow by 176.80% on average over the next years. This is a very strong growth
CTK is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.36% yearly.
EPS Next Y368.93%
EPS Next 2Y295.36%
EPS Next 3Y197.23%
EPS Next 5Y176.8%
Revenue Next Year9.94%
Revenue Next 2Y17.77%
Revenue Next 3Y17.07%
Revenue Next 5Y18.36%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CTK Yearly Revenue VS EstimatesCTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
CTK Yearly EPS VS EstimatesCTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 10 20 30

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 4.34, the valuation of CTK can be described as very cheap.
Compared to an average S&P500 Price/Earnings ratio of 26.34, CTK is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 0.93, the valuation of CTK can be described as very cheap.
When comparing the Price/Forward Earnings ratio of CTK to the average of the S&P500 Index (22.19), we can say CTK is valued rather cheaply.
Industry RankSector Rank
PE 4.34
Fwd PE 0.93
CTK Price Earnings VS Forward Price EarningsCTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.81
CTK Per share dataCTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

CTK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTK's earnings are expected to grow with 197.23% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y295.36%
EPS Next 3Y197.23%

More info and screens

0

5. Dividend

5.1 Amount

CTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COOTEK CAYMAN INC-ADR

NYSE:CTK (5/19/2022, 8:04:01 PM)

0.9111

+0.02 (+2.36%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)03-15 2022-03-15/bmo
Earnings (Next)06-06 2022-06-06/bmo
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap61.23M
Analysts45
Price Target66.3 (7176.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 4.34
Fwd PE 0.93
P/S 0.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -2.81
EPS(TTM)0.21
EY23.05%
EPS(NY)0.98
Fwd EY108.08%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS6.5
BVpS-0.09
TBVpSN/A
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -4.36%
PM (TTM) -5.95%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover7.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.82
Quick Ratio 0.82
Altman-Z 1.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)130.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y368.93%
EPS Next 2Y295.36%
EPS Next 3Y197.23%
EPS Next 5Y176.8%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y26.61%
Revenue growth 5Y89.97%
Sales Q2Q%-48.23%
Revenue Next Year9.94%
Revenue Next 2Y17.77%
Revenue Next 3Y17.07%
Revenue Next 5Y18.36%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A